Topic: National Cancer Research Network
Conditions
Interventions
Saracatinib 125mg per day or placebo for 28 days
Sponsors
Sheffield Teaching Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Able to give written informed consent and willing to follow the study protocol 2. Age = 16 years 3. Cytologically or histologically confirmed solid tumours of known primary site with painful bone metastases and poor control of bone pain 4. WHO performance status = 2 5. Average baseline pain score = 4 and = 9 on 10 numerical scale recorded over at least two separate days 6. Adequate baseline haematological, hepatic and renal function, defined as follows: Absolute neutrophil count = 1.5 x 109/L, Haemoglobin >9.0 g/dL (can be after transfusion), Platelet count = 100 x 109/L, Bilirubin = 1.5 x ULN, ALT or AST = 2.5 x ULN (= 5 x ULN if liver metastases), Creatinine = 1.5 x ULN 7. Ability to take and absorb oral medications 8. Female patients of childbearing potential (i.e. premenopausal females, females who have been menopausal for < 1 year and not surgically sterilized) must provide a negative pregnancy test (serum) = 7 days before study treatment begins and must agree to practice effective contraceptive measures (oral contraceptive pill, intrauterine device or diaphragm with spemicide) plus condoms during the study and for 30 days after last dose of saracatinib 9. Male patients with a partner of childbearing potential (who is not using an acceptable highly effective method of contraception) or a pregnant partner must use effective contraceptive measures (see 8) plus condoms during the study and for 3 months after the last dose of saracatinib. Patients should abstain from sperm donation during the study and for 3 months after the last dose of saracatinib
Exclusion criteria
Exclusion criteria: 1. Life expectancy less than 3 months 2. Previous or planned radiotherapy at site of pain 3. Unstable cardiac disease in last 3 months 4. History of interstitial lung disease (bilateral, diffuse parenchymal lung disease) in view of known saracatinib-related pneumonitis 5. Unable to discontinue any medication with known moderate or potent inhibitory effect on CYP3A4, or is a substrate of CYP3A4 6. Concomitant cytotoxic chemotherapy unless established on maintenance treatment for > 6 weeks (not in a clinical trial) 7. Unable to understand written or spoken English as the primary outcome is dependent on completion of the BPISF questionnaire
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score: Whether patients? self-reported pain scores are significantly lower after 4 weeks on treatment with | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed